Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Charles River Laboratories International, Inc. (CRL) Insider Trading Activity
Healthcare • Diagnostics & Research • 20,400 employees
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Total Value
-$2,887,831.60
Total Shares
18,556
Average Trade Value
-$144,391.58
Most Active Insider
Foster James C
Total Activity: $2,142,782
Largest Single Transaction
$1,130,346
by Foster James C on Jan 31, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
---|---|---|---|---|---|---|
Evp, Corp Strategy Develop
Officer
|
Feb 20, 2025 | 4,400 | $715,000 | 20,013 (-22.0%) | Sale | |
Chairman, President and CEO
Director, Officer
|
Feb 20, 2025 | 6,075 | $1,002,436 | 183,639 (+3.3%) | Purchase | |
Corporate Executive VP COO
Officer
|
Feb 20, 2025 | 1,514 | $249,250 | 55,058 (+2.7%) | Purchase | |
EVP Chief People Officer
Officer
|
Jan 31, 2025 | 791 | $130,966 | 16,506 (-4.8%) | Payment of Exercise Price | |
Corporate Executive VP CFO
Officer
|
Jan 31, 2025 | 914 | $151,331 | 11,550 (-7.9%) | Payment of Exercise Price | |
Corporate Executive VP CFO
Officer
|
Jan 31, 2025 | 2,704 | $10,000 | 12,464 (+21.7%) | Grant | |
Chairman, President and CEO
Director, Officer
|
Jan 31, 2025 | 19,608 | $10,000 | 204,391 (+9.6%) | Grant | |
Chairman, President and CEO
Director, Officer
|
Jan 31, 2025 | 6,827 | $1,130,346 | 197,564 (-3.5%) | Payment of Exercise Price | |
Evp, Corp Strategy Develop
Officer
|
Jan 31, 2025 | 2,738 | $10,000 | 25,259 (+10.8%) | Grant | |
Evp, Corp Strategy Develop
Officer
|
Jan 31, 2025 | 846 | $140,072 | 24,413 (-3.5%) | Payment of Exercise Price | |
EVP Chief People Officer
Officer
|
Jan 31, 2025 | 2,468 | $10,000 | 17,297 (+14.3%) | Grant | |
Cevp, Disc Safety Assessment
Officer
|
Jan 31, 2025 | 471 | $77,983 | 8,999 (-5.2%) | Payment of Exercise Price | |
Cevp, Disc Safety Assessment
Officer
|
Jan 31, 2025 | 1,758 | $10,000 | 9,470 (+18.6%) | Grant | |
Csvpchief Accounting Officer
Officer
|
Jan 31, 2025 | 811 | $10,000 | 9,137 (+8.9%) | Grant | |
Csvpchief Accounting Officer
Officer
|
Jan 31, 2025 | 282 | $46,691 | 8,855 (-3.2%) | Payment of Exercise Price | |
Corporate Executive VP COO
Officer
|
Jan 31, 2025 | 4,057 | $10,000 | 54,569 (+7.4%) | Grant | |
Corporate Executive VP COO
Officer
|
Jan 31, 2025 | 1,025 | $169,709 | 53,544 (-1.9%) | Payment of Exercise Price | |
Director
|
Nov 7, 2024 | 1,000 | $216,500 | 0 | Sale | |
Director
|
Nov 7, 2024 | 3,371 | $727,293 | 15,636 (-21.6%) | Sale | |
Director
|
Nov 7, 2024 | 3,250 | $703,625 | 12,386 (-26.2%) | Sale |